ADR - Adherium Limited

[System]

Adherium develops, manufactures and supplies digital health technologies that address suboptimal medicine use in chronic disease.

The Company's first product range is the Smartinhaler™ platform, comprising a range of approved medical devices that attach to prescription inhalers to monitor inhaler actuation and provide audio and visual medication reminders, and the SmartinhalerLive™ software, which integrates the data from the Smartinhalers into a usable form via communications protocols, mobile applications and cloud based software.

It is anticipated that ADR will list on the ASX during August 2015.

http://adherium.com

 

[greggles]

ADR making some gains this morning after announcing that its Board of Directors have recently purchased 1.4 million shares on the open market. That's a vote of confidence in the company by those who should best understand it and its potential.

However, ADR has generally been a real disappointment since it listed back in 2015, sinking from around 70c to 7c.

Last half yearly report detailed revenue of $2,661,000 and an operating loss of $4,978,000. Revenue was up 92% over the same period last year but the operating loss was about the same.

Today the share price is up 23.81% to 13c with volume of around 2.1 million shares traded.

 

[greggles]

ADR making some gains this morning after announcing that its Board of Directors have recently purchased 1.4 million shares on the open market. That's a vote of confidence in the company by those who should best understand it and its potential.

Well, well, well, what interesting timing for those purchases of shares by Adherium's Board of Directors. Two weeks later and there is an announcement that the U.S. Food and Drug Administration has granted 510(k) clearance for over-the-counter sales of the company's Smartinhaler sensor for AstraZeneca's Symbicort® aerosol asthma inhaler.

Co-incidence? Hmmm... I don't think so.

Adherium's share price climbed 54.17% today, finishing at 18.5c. A nice win for ADR's Board of Directors.

 

[Darc Knight]

Down 27% today. Has a buy rating by wallettinvestor lol

 

[Dona Ferentes]

Highlights:
• AstraZeneca has selected Adherium’s Hailie® Smartinhaler® platform for a
clinical trial.
• Hailie® technology to aid the collection of objective data for inhaler use in a clinical trial.
• Contract valued at $1.1M
.
AstraZeneca’s inhaled medication use will be recorded and transferred via Hailie Smartinhaler devices.

Adherium CEO, Dr. Paul Mastoridis, said: “This agreement underscores Adherium's strategic commitment to enhancing patient care through advanced technology.
Our Hailie® platform is designed to ensure precise monitoring and support for patients with respiratory diseases, facilitating the pursuit of tailored therapy."

Adherium will be providing Hailie® Smartinhalers®, Hailie® app and Platform for the trial, allowing for accurate tracking of inhaler medication use through the selected eCOA (Electronic Clinical Outcome Assessment) devices.

pushed to 3.1c on news but fell back